Form 8-K - Current report:
SEC Accession No. 0001193125-24-287170
Filing Date
2024-12-31
Accepted
2024-12-31 16:01:33
Documents
14
Period of Report
2024-12-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d848354d8k.htm   iXBRL 8-K 26435
  Complete submission text file 0001193125-24-287170.txt   184346

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20241227.xsd EX-101.SCH 3350
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20241227_def.xml EX-101.DEF 13625
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20241227_lab.xml EX-101.LAB 22654
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20241227_pre.xml EX-101.PRE 14403
17 EXTRACTED XBRL INSTANCE DOCUMENT d848354d8k_htm.xml XML 5996
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 241592955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)